ClinicalTrials.gg
CompletedNCT02039076Updated Dec 18, 2014

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

A Phase 1 interventional study of avatrombopag in Thrombocytopenia, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-18.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
13th of 23
48 · median 50
Started
2013
with 1 other
Phase 1
2 of 23
none open now
Registered
5th of 23
by date
Lead sponsor
5 of 23
Eisai Inc.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 13th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 1, and was the 5th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 20 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

This will be a randomized, open-label, 5-treatment-period study to evaluate the PK and PD of avatrombopag following a single administration of avatrombopag in the fed and fasted condition, or the fed condition, to healthy Japanese and white subjects. A standard high-fat, high calorie breakfast will be used to assess the fed condition.

Read the detailed description

The study will comprise a Prerandomization Phase and a Randomization Phase. The Prerandomization Phase will include 2 periods, Screening and Baseline 1. The Screening Period will be up to 3 weeks (21 days) in duration. The Randomization Phase will consist of 5 single-dose treatment periods, of which 3 will include administration of avatrombopag in the fed condition and 2 will include administration of avatrombopag in the fasted condition. Each treatment period will be separated by a wash out interval of at least 28 days. Before each treatment period, subjects will complete a baseline period (Baseline Periods 2, 3, 4, and 5), during which baseline assessments will be collected. A Final Visit will occur 28 days (+/- 1 day) after dosing in Treatment Period 5.

03

Conditions studied

  • Thrombocytopenia

Browse trials for

Keywords

  • Healthy
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. count between the lower limit of normal and 350 x 109/L, inclusive, at Screening and each Baseline; measurements can repeated for verification, if necessary
  2. Nonsmoking, healthy white and Japanese adult male and female subjects, greater than or equal to 20 years and less than or equal to 55 years old at the time of . (Nonsmokers are defined as those who have discontinued smoking for at least 4 weeks before dosing.)
  3. Japanese subjects must be born in Japan of Japanese parents and Japanese grandparents, must have lived no more than 5 years outside of Japan, and must not have changed their lifestyle or habits, including diet, while living outside of Japan.
  4. greater than or equal to 18 and less than or equal to 28 kg/m2 at Screening and Baseline Period 1. The BMI in white subjects must be within +/- 2 kg/m2 of the BMI in Japanese subjects.
  5. Nonsmoking, healthy white and Japanese adult males and females between the ages of 20 and 55, inclusive
  6. BMI between 18 and 28. inclusive
  7. Females must not be pregnant or lactating, and if they are of they must agree to use a highly effective method of or abstain
  8. Males must have a vasectomy or they and their partner must use a highly effective method of contraception

Exclusion criteria

Exclusion Criteria

  1. Evidence of organ dysfunction or any deviation from normal in their medical history (eg, history of splenectomy); history of arterial or venous thrombosis, including partial or complete thromboses (eg, stroke, , myocardial infarction, deep vein thrombosis, pulmonary embolism); known family history of hereditary thrombophilic disorders (eg, Factor V Leiden, antithrombin III deficiency)
  2. Recent clinically significant illness or infection that requires medical treatment
  3. Evidence of disease that may influence the outcome of the study (eg, psychiatric disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system), or subjects who have a congenital abnormality in metabolism
  4. Any history of gastrointestinal surgery (eg, hepatectomy, nephrotomy, digestive organ resection)
  5. Any clinically abnormal symptom or organ impairment found by medical history, physical examination, vital sign (ECG) assessment, or laboratory test results
  6. A known or suspected history of drug or alcohol dependency or abuse or a positive urine drug, cotinine, or alcohol test
  7. Positive results for (HIV), surface antigen (HBsAg), or virus (HCV) antibody at Screening
  8. Weight loss or gain of >10% within 4 weeks before dosing
  9. Known history of clinically significant drug or food allergy
  10. Currently enrolled in another clinical trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    avatrombopag

    Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.

    Drug: avatrombopag

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) profiles of avatrombopag

    The following PK parameters will be estimated for plasma: Cmax, AUC, and t1/2.

    Time frame: Up to 23 Weeks

Secondary outcomes

  1. Pharmacodynamic (PD) profiles of avatrombopag

    Analyses will carried out for AUEC(0-28d) and Emax using a mixed linear model including fixed terms for dose, race, food, sequence, and period with interaction terms for food by race and for dose by race and subject as random effect.

    Time frame: Up to 23 Weeks

  2. Comparison of PK and PD for avatrombopag

    To assess the similarity of the PK and PD of avatrombopag between healthy Japanese and white subjects after a single administration of avatrombopag under fasted conditions

    Time frame: Up to 23 Weeks

  3. Adverse events (AEs ) as a measure of safety and tolerability

    Saftey assessments include AEs, clinical laboratory results, vital signs, and ECGs.

    Time frame: Up to 23 Weeks

  4. Laboratory assessments as a measure of safety and tolerability

    Clinical laboratory assessments will include haematology, clinical chemistry, urinalysis and other screening tests

    Time frame: Up to 23 Weeks

  5. Vital signs as a measure of safety and tolerability

    Vital sign measurements will include systolic and diastolic blood pressure (BP) and pulse rate

    Time frame: Up to 23 Weeks

  6. Electrocardiogram (ECG) as a measure of safety and tolerability

    Twelve-lead ECGs will be obtained as a measure of safety and tolerability

    Time frame: Up to 23 Weeks

07

Study locations

1 site
  • Parexel International Early Development Clinical Units
    Glendale, California, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jun 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2014
First posted
Jan 17, 2014
Start
Dec 2013
Primary completionActual
Jun 2014
CompletionActual
Sep 2014
Last update
Dec 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02039076
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 17, 2014
Start date
Dec 2013
Primary completion
Jun 2014
Completion
Sep 2014
Last update
Dec 18, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion